<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are characterized by dyserythropoiesis resulting in <z:hpo ids='HP_0001903'>anemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>This pathological hallmark is incompletely understood </plain></SENT>
<SENT sid="2" pm="."><plain>Notch signaling has been linked to impaired erythropoietic and megakaryopoietic development of CD34+ progenitor cells, but its role in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> is unclear </plain></SENT>
<SENT sid="3" pm="."><plain>We have analyzed the transcriptional activity of Notch pathway elements and its association with the key erythroid factor <z:chebi fb="0" ids="5386">globin</z:chebi> transcription factor 1 (GATA1) and the <z:mpath ids='MPATH_3'>apoptosis</z:mpath> regulatory gene B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>-xl (BCLxl) in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The methylation of GATA1 erythroid promoter CpG <z:chebi fb="0" ids="47885">dinucleotides</z:chebi> flanking cis-regulatory elements, including an N-box suppressor binding site for HES1 and a GATA-box binding site, was examined in <z:mpath ids='MPATH_458'>normal</z:mpath> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> erythropoiesis </plain></SENT>
<SENT sid="5" pm="."><plain>We have generated a kinetic in vitro model of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> erythropoiesis using CD34+ bone marrow cells from healthy donors (n = 7) and patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (low risk: RA/n = 6, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>/n = 3; high risk: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>/n = 4, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>/n = 2) </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="40" ids="33697">RNA</z:chebi> expression of GATA1, BCLxl, DLK1, Notch1, HES1, and HERP2 was measured by real-time RT-PCR (qPCR) </plain></SENT>
<SENT sid="7" pm="."><plain>DNA methylation at seven CpG <z:chebi fb="0" ids="47885">dinucleotides</z:chebi> of the GATA1 gene promoter was quantitatively analyzed by pyrosequencing of <z:chebi fb="0" ids="17137">bisulfite</z:chebi>-treated genomic DNA at any specific time point </plain></SENT>
<SENT sid="8" pm="."><plain>For the Notch pathway elements, no conclusive expression differences were found between <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:mpath ids='MPATH_458'>normal</z:mpath> erythropoiesis </plain></SENT>
<SENT sid="9" pm="."><plain>But we found steadily up-regulated <z:chebi fb="40" ids="33697">RNA</z:chebi> expression of GATA1 and of BCLxl during late <z:mpath ids='MPATH_458'>normal</z:mpath> erythropoietic differentiation </plain></SENT>
<SENT sid="10" pm="."><plain>In contrast, during <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, erythropoiesis a loss of typical up-regulation of GATA1 and BCLxl was observed </plain></SENT>
<SENT sid="11" pm="."><plain>Hypermethylation of CpG <z:chebi fb="0" ids="47885">dinucleotides</z:chebi> flanking the repressor HES1 binding site within the 5' region of GATA1 was detected particularly during late <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> erythropoiesis </plain></SENT>
<SENT sid="12" pm="."><plain>Interestingly, decremental GATA1 promotor methylation values were seen during <z:mpath ids='MPATH_458'>normal</z:mpath> erythropoiesis matching GATA1 <z:chebi fb="40" ids="33697">RNA</z:chebi> up-regulation </plain></SENT>
<SENT sid="13" pm="."><plain>Our data show that the critical erythropoietic transcription factor GATA1 as well as the antiapoptotic molecule BCLxl fails to be normally up-regulated during <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> erythropoiesis </plain></SENT>
<SENT sid="14" pm="."><plain>The higher residual 5'-GATA1 methylation values in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> erythropoiesis but decremental loss thereof in <z:mpath ids='MPATH_458'>normal</z:mpath> erythropoiesis suggest a gene dose effect for GATA1 during erythropoiesis being finely tuned by CpG methylation </plain></SENT>
<SENT sid="15" pm="."><plain>Its dysregulation may contribute to the <z:hpo ids='HP_0010972'>ineffective erythropoiesis</z:hpo> observed in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>